Gilead Sciences, Inc. $GILD Shares Sold by Financiere des Professionnels Fonds d investissement inc.

Financiere des Professionnels Fonds d investissement inc. decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 96.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,200 shares of the biopharmaceutical company’s stock after selling 36,150 shares during the quarter. Financiere des Professionnels Fonds d investissement inc.’s holdings in Gilead Sciences were worth $167,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the 4th quarter worth $25,000. Vermillion & White Wealth Management Group LLC boosted its position in shares of Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares during the last quarter. Quattro Advisors LLC acquired a new position in shares of Gilead Sciences during the 4th quarter valued at about $26,000. Wealth Preservation Advisors LLC grew its holdings in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 81 shares during the period. Finally, Ares Financial Consulting LLC acquired a new stake in Gilead Sciences during the fourth quarter worth about $28,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Rothschild & Co Redburn cut their price target on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Citigroup lifted their price target on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Leerink Partners lowered their price objective on Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Finally, HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Twenty-six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $159.04.

Gilead Sciences Price Performance

Shares of GILD opened at $134.28 on Friday. The firm has a 50-day simple moving average of $129.73 and a two-hundred day simple moving average of $135.22. The stock has a market cap of $166.72 billion, a PE ratio of 18.29 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $107.75 and a 1-year high of $157.29. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post -0.77 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were given a $0.82 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. Gilead Sciences’s payout ratio is presently 44.69%.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the transaction, the chief executive officer directly owned 607,133 shares in the company, valued at $76,674,826.57. This represents a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 77,000 shares of company stock worth $9,978,740 over the last ninety days. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.